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Advances  in  DNA  sequencing  technology  now  allow  for  the  rapid  genome-wide  identiﬁcation  of inherited
and  acquired  genetic  variants  including  those  that  have  been  identiﬁed  as  pathogenic  alleles  for  a number
of  diseases  including  cancer.  Whole  genome  and exome  sequencing  are  increasingly  becoming  a  part
of  both  clinical  practice  and research  studies.  In 2013  the  American  College  of  Medical  Genetics  and
Genomics  (ACMG)  recommended  that  results  of  pathogenic  genetic  variants  in 56  genes,  nearly  half  of
which  comprise  cancer  genes  (including  BRCA1,  BRCA2,  TP53,  MLH1,  MLH2,  MSH6,  PMS2,  and  APC),  be
returned  to  patients  who  have  their  genome  sequenced  independent  of  the purpose  for  the test.  This
recommendation  has  been  highly  controversial  for several  reasons,  particularly  the  recommendation
that  individuals  be returned  secondary  ﬁndings  of  disease  causing  variants  for adult onset  conditions
regardless  of age  and  without  consideration  of  patient  preferences.  In  addition,  the  policy  regarding
returning  results  of  secondary  ﬁndings  from  genomic  sequencing  studies  in  research  settings  is  currently
unclear.  In  response  to  these  emerging  ethical  issues,  the Washington  University  Brown  School  of  Socialesting
RCA1
Work  in  St.  Louis,  MO,  United  States  hosted  a policy  forum  entitled  “First  do no harm:  Genetic  privacy  in
the age  of  genomic  sequencing”  on February  25th,  2014.  The  forum  included  a panel  of experts  to discuss
their  views  on  ethical  issues  related  to  return  of  results  in  both  the  clinical  and  research  settings.  In  this
report, we  highlight  key  issues  related  to return  of results  from  genome  sequencing  tests  that  emerged
during  the forum.
©  2014  Published  by Elsevier  Ltd.  This  is an  open  access  article  under the  CC  BY-NC-ND  licensentroduction
The completion of the human genome sequence in 2003 [1]
as been followed by rapid advances in genomic technology and
ubsequent exponential increases in knowledge of human genetic
ariation, including that associated with both Mendelian and
on-Mendelian diseases. Plummeting costs of genome sequenc-
ng technology [2] make it increasingly feasible to rapidly scan
he whole genome (both genic and non-genic DNA sequence) and
xome (genic DNA sequence) for inherited variants including those
hat have been previously identiﬁed or suspected as pathogenic
lleles for cancer. Genome-wide genetic testing offers the potential
o identify high risk populations for cancer prevention and con-
rol, which could ultimately lead to reductions in cancer morbidity
nd mortality. As a consequence, there has been intense interest in
∗ Corresponding author at: Campus box 1196, Washington University in St. Louis,
ne Brookings Drive, St. Louis, MO 63130, USA. Tel.: +1 314 935 3550.
E-mail address: sgehlert@wustl.edu (S. Gehlert).
ttp://dx.doi.org/10.1016/j.jcpo.2014.05.001
213-5383/© 2014 Published by Elsevier Ltd. This is an open access article under the CC B(http://creativecommons.org/licenses/by-nc-nd/3.0/).
developing guidelines for returning results of pathogenic variants
that are detected in genome sequencing tests for diseases, including
cancer, for which prevention and/or early intervention is possible.
In March 2013, the American College of Medical Genetics
and Genomics (ACMG), an organization that supports the medi-
cal genetics profession, published recommendations for reporting
what was termed “incidental ﬁndings” of pathogenic variants
detected in genomic sequencing tests [3]. The ACMG recommended
that pathogenic or presumed pathogenic variants in 56 genes be
reported to individuals who have their genome sequenced. The
report deﬁned incidental ﬁndings as “the results of a deliberate
search for pathogenic or likely pathogenic alterations in genes that
are not apparently relevant to a diagnostic indication for which the
sequencing test was  ordered” [3]. However, on the basis of a deﬁ-
nition published by the U.S. Presidential Commission for the Study
of Bioethical Issues, we  use the term “secondary ﬁndings” through-
out the manuscript in lieu of “incidental ﬁndings” to describe the
active search for variants in genes recommended by the ACMG [4].
The genes were selected by the committee on the basis of their
medical actionability. Nearly half of the recommended genes are
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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ell-known cancer susceptibility genes including: BRCA1,  BRCA2,
P53, STK11,  MLH1,  MLH2,  MSH6,  PMS2, APC, MUTYH, VHL,
EN1, RET, PTEN, RB1, TSC1, TSC2, WT1, and NF2. The ACMG
ecommendation has been highly controversial, in particular
he recommendation that results be returned to parents/legal
uardians of children for pathogenic variants in genes associated
ith adult onset conditions. In addition, the lack of patient auton-
my  over whether to receive secondary ﬁndings in their clinical
equencing data has also been a subject of intense debate [5,6].
In response to these emerging policy issues, on February 25th,
014, Washington University in St. Louis, MO,  United States hosted
 90 min  policy forum entitled “First do no harm: Genetic privacy
n the age of genomic sequencing” that featured a panel of experts
oncerned about ethical issues associated with genomic sequenc-
ng (panelist biographies are provided in the Appendix). We  note
hat the debate generated by the ACMG report is not speciﬁc to
he U.S. [7,8] nor is it the only position articulated in the U.S., but
he forum mainly focused on this report as a starting point for the
olicy conversation. The 90 min  policy forum format allowed for
onsiderable audience discussion following each 4–7 min  panelist
resentation on return of results in both clinical and research sett-
ngs (video is available upon request). In this report, we discuss key
ssues regarding return of results that emerged during the policy
orum.
eturn of results in clinical settings
The central controversy surrounding return of results from
hole genome or exome sequencing tests in clinical settings is
hether patients should have the choice of receiving secondary
ndings that are detected during testing that was performed for
ther purposes. The panelists expressed opposing viewpoints on
his controversy. Lainie Ross, MD,  PhD, Professor of Clinical Med-
cal Ethics at the University of Chicago, pointed out that patients
ave the right not to be informed of results from genetic tests
or reasons including: the information may  not be relevant for
ecades, the information may  inaccurately predict risk, the infor-
ation may  only be wanted if effective treatments or preventions
re available, and the tests may  reveal unanticipated informa-
ion that might produce harm (e.g., misattributed paternity). Other
xperts believe that the rationale for treating return of results of
econdary/incidental ﬁndings from genomic sequencing differently
han return of results from other types of medical tests is unclear
5]. Laura Bierut, MD,  Professor of Psychiatry at the Washington
niversity School of Medicine raised this issue during her opening
emarks in a thought experiment. If a patient gets a chest X-ray
nd the radiologist notes a lesion incidental to the purpose of the
maging, shouldn’t the radiologist tell the doctor and the doctor
ell the patient? She emphasized that if the healthcare provider
elieves that the ﬁnding may  be life changing, that it should be
rovided to the patient. For further discussion of this analogy see
olomon 2014 [9]. Ellen Wright Clayton, JD, MD,  Professor of Pedi-
trics at Vanderbilt University School of Medicine and Professor of
aw at Vanderbilt University School of Law, emphasized the point
bout deﬁnitions of types of ﬁndings in her opening remarks; the
CMG recommendation for reporting variants in 56 genes does
ot actually constitute reporting of ‘incidental’ ﬁndings as was
eﬁned by the ACMG report. One must actively search for, sequence
nd analyze these genes for variants, which as Dr. Ross noted,
andates the addition of opportunistic screening any time whole
enome sequencing is performed. It requires the clinical laboratory
o actively sequence, analyze, and interpret variants in 56 highly
enetrant genes, and if found, report them back to the physician.
he believes that this poses serious ethical issues including: (1) it
oes not require the consent of the ordering physician or patient,
nd (2) there is predictive uncertainty—i.e., pathogenic variants inancer Policy 2 (2014) 75–80
genes identiﬁed by the ACMG may  be highly penetrant in high-risk
populations where the most research has been conducted but it is
unclear whether the same is true for populations where research
has not been conducted.
Return of results in research settings
The issues surrounding return of results from genomic sequenc-
ing studies in research settings differs from clinical settings.
Jonathan Green, MD,  Executive Chair of the Washington Univer-
sity Institutional Review Board (IRB) reminded the audience that
the IRB is charged with determining that research involving human
subjects meets speciﬁc regulatory criteria (45 CFR 46.111) that are
derived from the Belmont Principles [10]. Human subjects’ regu-
lations require that informed consent include a statement that the
study involves research. Returning genetic information, particularly
if unrelated to the aims of the study, crosses into the realm of clinical
medicine. Individuals who enroll in research studies where there
is a promise made to return results and secondary ﬁndings, are
likely to equate this with going to their primary care doctor and
having a test done for clinical purposes. Dr. Green noted that the
informed consent document must include a description of any rea-
sonable foreseeable risks or discomforts as well as beneﬁts to the
subject. Because anticipated and secondary ﬁndings that are gen-
erated in genomic research meet the standard of being reasonably
foreseeable, the informed consent process must clearly disclose the
possibility of returnable results and secondary ﬁndings and their
implications for the participant. It is less clear, according to Dr.
Green, whether returning results on secondary ﬁndings should be
considered a risk or a beneﬁt. In ideal circumstances, the beneﬁt is
obvious. That is to say, the participant is made aware of a medical
condition for which an action can be taken, and a poor outcome
is averted. However, Dr. Green stressed that potential harms may
also occur when participants receive results including unnecessary
additional tests and procedures each with their own  associated
costs, risks, and morbidities. For example, the penetrance of BRCA1
pathogenic variants may  be lower in the general community than
in those women  who  have a family history of breast cancer [11].
Returning results to women  for rare BRCA1 variants with uncer-
tain penetrance could lead to potential harms including leading
some women to undergo prophylactic measures to reduce their
risk [12,13].
Dr. Green discussed the current state of affairs for guidelines on
return of results in research settings. Current United States regula-
tions require that participants be fully informed about the nature
of the research, and therefore they must be informed about the
possibility of research results or secondary ﬁndings being gener-
ated in a study. Furthermore, they must be informed about what
the researcher plans to do with the information (return them or
not). If results are to be returned, participants should be asked
at the outset whether they want the results, ideally at the time
of informed consent, and then perhaps again at the time they
are available. When returned, risks must be minimized by assur-
ing the results are valid and that the participant is provided with
appropriate resources and follow-up to act on the information.
Dr. Green stated that he does not believe that current regulations
require researchers to routinely look for secondary ﬁndings, nor
to always promise to return research results or secondary ﬁnd-
ings. Nor does he believe that it should be made mandatory for
researchers to do so. Mandating return of results promotes con-
fusion between the roles of researcher and clinician, as well as
the roles of participants and patients. Research is not clinical care
and the researcher–participant relationship is not the same as
the physician–patient relationship. Researchers should be wary of
accepting new obligations that cross over into the clinical realm.
Imposing a mandatory duty on all researchers to look and warn,
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laces undue burdens on the research enterprise. Such a require-
ent may  force researchers to make promises they cannot keep. Dr.
reen noted that furthermore, it will be impossible to ensure that
he results are returned in a way that minimizes risk, by providing
alid results, with appropriate counseling and follow up. Doing this
oorly is worse than not doing it at all, he noted.
ssues related to return of results across settings
he concept of “To do no harm”
The panel was asked by the moderator (S. Gehlert) for their
iews on the consistency between the ACMG recommendations
nd the “to do no harm” concept in medicine and healthcare ethics.
r. Green noted that explicitly following the ACMG recommenda-
ions runs counter to this concept in medicine because there is no
rocess for informed consent of the patient. He also noted that the
mpact of all mutations on disease risk is not understood. “To do no
arm” comes with “respect for persons” [10], the ability of indi-
iduals to make their own choices as to what information they
eceive. Vence L. Bonham, JD, Associate Investigator, Division of
ntramural Research, Social and Behavioral Research Branch and
enior Advisor to the U.S. National Human Genome Research Insti-
ute (NHGRI) Director on Genomics and Health Disparities, NHGRI
oncurred that the question of harm is complex. This sentiment was
lso echoed by Dr. Clayton, who gave the example that parents of
hildren with life-threatening diseases (children who  may  be more
ikely to have their genomes sequenced), may  not want anymore
bad news”. In contrast, the reality, as Dr. Bierut pointed out, is that
enetics is entering clinical practice, and the more salient issue is
ow best to consent and deliver secondary ﬁndings. The informed
onsent process for clinical sequencing should inform individuals
f the potential of uncovering of deﬁned incidental ﬁndings, such
s genetic cancer predispositions, and patients who do not want to
eceive these results should consider not undergoing genetic test-
ng. In contrast, as Dr. Ross suggested, it seems likely that patients
ay  not wish to know all that can be known about their health.
espect for persons [10] requires that patients have a choice over
hether to receive secondary ﬁndings from genetic testing. Dr. Ross
lso suggested that providing individuals in the clinical setting with
 choice not to get sequenced is not a solution because it may  be
he only way to obtain a diagnosis.
An important consideration raised by an audience member
elated to the concept of “to do no harm” regards the evidence on
arms, such as anxiety and distress, after receiving genetic results.
r. Bierut gave the example of return of results for Apolipopro-
ein E (APOE), a gene where certain common alleles have been
ssociated with a strongly increased risk for Alzheimer’s disease
AD), from The Risk Evaluation and Education for Alzheimer’s dis-
ase (REVEAL) study. The objective of the REVEAL study was  to
etermine the effect on depression and anxiety up to 1 year after
eturning APOE risk allele (4) results to individuals who did not
ave AD symptoms. Participants were randomized to either dis-
losure of results for the risk allele or non-disclosure. The authors
eported no signiﬁcant differences between the two groups in anx-
ety or depression up to one year [14]. However, Dr. Clayton noted
hat the REVEAL study was comprised of individuals who were
lready aware of their AD risk because of family history, were
xtensively counseled about AD risk as part of their participation,
nd had consented to the study. Dr. Green also commented that
he generalizability of ﬁndings from this study is limited by the
ighly controlled research setting in which the study took place
nd it is not clear how these results will extrapolate to the general
opulation. However, additional evidence shows that anxiety and
istress is transient after receiving genetic results, even potentiallyancer Policy 2 (2014) 75–80 77
life altering incidental ﬁndings such as cancer predisposition risk.
A study of the effects of direct to consumer testing identiﬁed indi-
viduals who carried BRCA variants, the variants which carry a high
predisposition to breast and ovarian cancer. In follow up, there was
no signiﬁcant evidence of serious emotional distress or inappro-
priate actions by the individuals [15]. Research funded by the U.S.
NHGRI should help to further clarify the issue of harms and beneﬁts
of returning genetic information pertaining to secondary ﬁndings.
Inequities in genomic studies
The issue of equality in knowledge about genetic variation
between different ancestral groups was  also identiﬁed during the
policy forum as a major issue related to return of genomic sequenc-
ing results. The vast majority of genomic knowledge on human
genetic variation is derived from individuals of European descent.
Mr.  Bonham emphasized this issue and the issue of who  has access
to genome sequencing that could beneﬁt patient outcomes. He dis-
cussed the principle of justice and fairness in health inequities
recommendation 5 from a report by the U.S. Presidential Com-
mission for the Study of Bioethics [4]: “The principle of justice and
fairness requires that all individuals have access to adequate informa-
tion, guidance, and support in making informed choices about what
medical tests to undergo, what kind of information to seek, and what
to do with the information once received. The principle of justice and
fairness also requires affordable access to quality information about
incidental and secondary ﬁndings, before and after testing, which when
coupled with access to care can be potentially lifesaving or life enhanc-
ing.” Mr.  Bonham noted that this is an audacious recommendation
but contended that we  need to understand the barriers to affordable
access to clinical use of genomic data for all patient populations.
In addition, the issue of who will beneﬁt from return of results
needs to be addressed. Even if diverse communities have access to
clinical sequencing genotype based testing, it is not clear that they
will beneﬁt. Knowledge of genetic variation in non-Northern Euro-
pean populations is markedly less in comparison to that of Northern
European populations that have been most well studied—which
could impact interpretation of genome testing results. Dr. Bon-
ham referenced a study by Dorschner et al. [16] that examined
‘pathogenic incidental ﬁndings’ in 1000 exomes from 500 Euro-
pean and 500 African-descent individuals. The authors examined
114 genes associated with medically actionable conditions for dis-
ease causing variants that were listed in the Human Gene Mutation
Database (HGMD) [17]. The authors reported that 23 participants
with variants that were listed in HGMD were “disproportionately”
of European descent (n = 17) versus African descent (n = 6). These
data highlight that any beneﬁt derived from returning results of
secondary ﬁndings will disproportionately apply to individuals
of European descent. Mr.  Bonham concluded that if ancestrally
diverse groups are not included in research, they may  not bene-
ﬁt to the same extent as those populations that are included and
that there is much to do to ensure that the health beneﬁt of clinical
sequencing and genotype guided treatment is equally accessible to
all communities. An audience member echoed this point with the
comment that the focus of the policy discussion really should not
be about whether to give people information but instead about who
has access to information.
Health literacy
Another issue raised during the forum is the issue of health lit-
eracy, deﬁned by the Institute of Medicine as “the degree to which
individuals have the capacity to obtain, process, and understand
basic health information and services needed to make appro-
priate health decisions” [18]. Even if informed consent of the
patient/research participant for return of results is obtained, it
7 al of C
i
s
t
s
i
t
t
N
o
t
h
m
l
m
t
t
e
p
[
g
p
f
s
i
o
t
t
t
h
R
i
“
t
d
c
e
o
t
d
c
i
g
b
o
s
r
d
a
e
f
t
h
i
t
a
o
m
b
t
u
f
r
ing “. . .that patients should have an opportunity to opt out of the
analysis of medically actionable genes when undergoing whole
exome or genome sequencing” [27]. Of note is that the issue of8 K.J. Johnson, S. Gehlert / Journ
s unclear that individuals who opt to receive information on
econdary genomic ﬁndings will understand the potential implica-
ions. These may  include: the possibility of genetic discrimination,
trengths and limitations of genomic data, and implications of test-
ng children. The need for increased genomic health literacy among
he general U.S. population was recently emphasized in a study
hat surveyed 2500 adults following the actress Angelina Jolie’s
ew York Times editorial [19] announcing that she was a carrier
f the BRCA1 mutation and had chosen to have a double mastec-
omy. The survey results indicated that although 75% of adults had
eard her story, less than 10% knew the relationship between BRCA1
utations and breast cancer risk [20].
Obtaining informed consent in the clinical setting may  be chal-
enging as alluded to by Dr. Bierut. Although healthcare providers
ay  wish to ensure that their patients have an understanding of
he implications of agreeing to the return of results from genomic
esting, the limited time spent in patient care may  be a barrier. For
xample, a U.S. study published in 2012 that examined 2470 cancer
atient ofﬁce visits reported that the average duration was  22.9 min
21]. Since cancer patients are likely to be one of the largest patient
roups to undergo clinical sequencing, the ability of healthcare
roviders to obtain informed consent has important implications
or considering return of secondary ﬁndings. Dr. Bierut noted that
pending more time on educating patients about genomic test-
ng and the implications of the results will come at the expense
f other conversations related to clinical care, and she emphasized
hat alternate delivery systems such as delivery of genetic informa-
ion through the internet (as has been done in direct-to-consumer
esting) may  provide a solution to this challenge. Research on the
arms and beneﬁts of new health communication tools is needed.
eturn of results to children
The ACMG recommended that age not be considered as a factor
n the return of results (The Working Group recommended that
incidental variants should be reported regardless of the age of
he patient”) [3]. According to the ACMG report, this recommen-
ation was based on a number of considerations including: (1)
oncerns that reporting of secondary ﬁndings relevant to adult dis-
ase may  be the only way that parents themselves become aware
f the pathogenic variant that affects them; (2) laboratory capacity
o mask variants identiﬁed in clinical sequencing tests for chil-
ren speciﬁcally; and (3) a favorable risk beneﬁt ratio of providing
hildren with results of genomic testing for adult onset diseases
n cases where intervention is possible [3]. Some evidence sug-
ests that parents want these results. For example, a 2013 study
y Sapp et al. [22] examined parental preference for receiving sec-
ndary ﬁndings in their children with undiagnosed diseases and
uggested that although parents express preference for receiving
esults on variants associated with actionable disorders that occur
uring childhood, they are less likely to agree to receive results
bout adult-onset diseases for which there is no treatment. An audi-
nce member reported that in her experience as a clinical genetics
ellow, parents rarely opt out of receiving results. Moreover, no long
erm data currently exists on any harms that emerge during adult-
ood in individuals who were returned results as children. There
s clearly a need for longitudinal research to understand harms
o individuals who are returned results as minors. Interestingly,
 statement prepared by the ACMG and the American Academy
f Pediatrics published a month before the ACMG report, recom-
ended that genetic testing in children for adult-onset conditions
e deferred [23]. Dr. Ross pointed out that even when a BRCA muta-
ion is found, mammograms are not recommended for individuals
ntil they are adults. However, as noted above, one of the rationales
or this ACMG recommendation was that “an incidental ﬁnding
elevant to adult disease that is discovered and reported to theancer Policy 2 (2014) 75–80
clinician through clinical sequencing of a child may be the only way
which the variant will come to light for the parent” [3]. In other
words, a BRCA1 pathogenic variant that is identiﬁed in the child
through genomic testing may  have implications for cancer risk in
the parent, even though, as Dr. Ross emphasizes, the gene may  not
be pathogenic in this family and its identiﬁcation may  cause more
harm (e.g., stress and unnecessary surveillance) than beneﬁt.
Predictive uncertainties in genetic testing results
The predictive uncertainty of genetic variants from genomic
testing, including ACMG recommended genes (particularly BRCA1
and 2) emerged as another important issue. Dr. Ross described
the ACCE model process for evaluating genetic tests that provides
criteria for returning results to patients [24]. The ACCE model
considers Analytic Validity, Clinical Validity, Clinical Utility, and
Ethical, Social and Legal Implications. Evaluation using the ACCE
criteria suggests that returning secondary genomic testing results
may  not necessarily meet the criteria, particularly with respect to
clinical validity. For example, the signiﬁcance of some variants,
including those in the breast cancer susceptibility genes BRCA1
and 2, may  not always be known, especially in individuals where
there is no family history of breast cancer. BRCA1 or 2 pathogenic
variants that have previously been identiﬁed in high risk fami-
lies may  be highly penetrant in these communities but penetrance
in the general population is not as well understood. For exam-
ple, a recent well-designed study conducted in the Netherlands
indicated a lower penetrance of breast cancer in BRCA1 mutation
carriers in families with fewer breast cancer cases versus those
with more cases (although the life time risk was still higher than in
non-carriers). This data emphasizes that genotype phenotype cor-
relations may  be less strong than previously thought, as well as the
need to consider gene environment interactions [25].
The concept of predictive uncertainty of genomic sequence
ﬁndings is also important to consider when offering research par-
ticipants results from genomic sequencing as Dr. Green commented
on in his opening remarks. Minimization of risk requires that any
sequence results reported back to participants be analytically valid
and that participants are provided with adequate counseling and
resources to be able to interpret the result and to determine appro-
priate next steps. This is challenging for IRBs to evaluate and
research teams to implement. There are questions about what con-
stitutes analytic validity in the research setting where tests are
not required to be conducted in a Clinical Laboratory Improvement
Amendments (CLIA)-certiﬁed laboratory that meets standards for
U.S. laboratory testing [17,26]. Requiring that sequencing be con-
ducted in a CLIA-certiﬁed environment in research settings may  be
prohibitively expensive. In addition, it may  also be prohibitively
expensive to include a genetic counselor on any research projects
that generate genomic sequencing data.
Update on ACMG recommendations
The authors would like to note that a little over a month
(April 1, 2014) after the policy forum on this topic was  held, the
ACMG published a revision to their 2013 recommendation stat-the impracticality of pre-test counseling of patients about sec-
ondary ﬁndings in the 56 genes that served as one of the reasons
for not giving patients an opportunity to opt out still needs to be
addressed.
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ummary and future directions
From the policy forum, it became clear that much work is still
eeded to inform and develop policies on the return of results
rom genomic testing. Clinical sequencing is being implemented
apidly in medicine making this topic an urgent area for pol-
cy research, discussion, and formulation. Experts and community
udience members did not necessarily agree about whether sec-
ndary results from genomic testing should be returned and under
hich circumstances. Several issues emerged that indicated a clear
eed for additional research and community input to further inform
olicy formulation. These issues include: return of results to chil-
ren, health literacy, inequities in genomic testing, alternative
odes of delivering genetic information outside of traditional clinic
ettings, and predictive uncertainties in risk associated with genetic
esting results. It is clear that advances in our ability to detect and
dentify human genetic variation associated with cancer suscepti-
ility and other diseases have enormous potential for prevention
nd early treatment. However, we must continue to be thoughtful
bout issues related to inequities in genomic data and how best
o deliver genomic testing results that hold immense promise for
educing disease morbidity and mortality.
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